Black Rock Inc. Gh Research PLC Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Gh Research PLC stock. As of the latest transaction made, Black Rock Inc. holds 62,315 shares of GHRS stock, worth $742,171. This represents 0.0% of its overall portfolio holdings.

Number of Shares

62,315

Previous 17,908 247.97%

Holding current value

$742,171

Previous $103,000 544.66%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$5.34 - $11.09 $237,133 - $492,473	44,407 Added 247.97%	62,315 $664,000
Q4 2023 Feb 13, 2024	SELL	$5.26 - $11.04 $33,958 - $71,274	-6,456 Reduced 26.5%	17,908 $103,000
Q3 2023 Nov 13, 2023	BUY	$9.8 - $14.15 $93,570 - $135,104	9,548 Added 64.44%	24,364 $244,000
Q2 2023 Aug 11, 2023	BUY	$7.88 - $12.74 $77,484 - $125,272	9,833 Added 197.33%	14,816 $175,000
Q1 2023 May 12, 2023	SELL	$6.02 - $10.92 $1,300 - $2,358	-216 Reduced 4.15%	4,983 $39,000

Q4 2022 Feb 13, 2023	SELL	$9.2 - $13.5 $131,744 - $193,320	-14,320 Reduced 73.36%	5,199 $50,000
Q3 2022 Nov 14, 2022	SELL	$10.15 - $16.15 $15,905 - $25,307	-1,567 Reduced 7.43%	19,519 $227,000
Q2 2022 Aug 12, 2022	BUY	$8.99 - $19.87 $37,722 - $83,374	4,196 Added 24.84%	21,086 $210,000
Q1 2022 May 12, 2022	BUY	$15.48 - $23.98 $186,611 - $289,078	12,055 Added 249.33%	16,890 $309,000
Q4 2021 Feb 10, 2022	BUY	$14.1 - $27.9 $68,173 - $134,896	4,835 New	4,835 $113,000
Q3 2021 Nov 09, 2021	SELL	$16.51 - $23.68 $16,510 - $23,680	-1,000 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$19.25 - $21.73 $19,250 - $21,730	1,000 New	1,000 $21,000

Others Institutions Holding GHRS

# of Institutions

Shares Held

17M

Call Options Held

25.5K

Put Options Held

19.8K

View Full List

About GH Research PLC

Ticker GHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,020,800
Market Cap $620M
Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...

More about GHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account